CBD Study Proves Beneficial Effects in Anxiety and Sleep Problems

A study supporting the reputation of CBD as having anxiolytic effects has been released. The study, published by Medscape, was a Phase IV trial conducted as an open-label, randomized controlled trial. It included 2,704 participants aged 21 years or older with anxiety, sleep disorders, or chronic pain. Intermediate results were encouraging, with 63% of participants reporting a decrease in anxiety.

CBD, or cannabidiol, is a substance derived from cannabis. It has been on sale for a short time in France in specialized stores. The motivations of consumers are diverse. A new study would support its reputation as an anxiolytic substance.

For more CBD and cannabis updates, check out our free cannabis news app.

There’s More to Study in CBD

Cannabis contains many cannabinoid substances, the two best known being cannabidiol (CBD) and tetrahydrocannabinol (THC). While THC has psychoactive properties and generates a dependence for the consumer, it is not the case with CBD. Recently, it is sold freely in France in specialized stores that are flourishing everywhere. CBD is available in the form of cartridges for electronic cigarettes, oils, herbal teas, cakes…

CBD has the reputation of having anxiolytic, anti-inflammatory, and analgesic properties, however further study is still required. Even if elements from basic research support these hypotheses, there is no or very little clinical data to confirm or deny them. This is the objective of the Advancing CBD Education and Science (ACES) trial.

A New Kind of Study

The study, published by Medscape, was conducted in real life, as a Phase IV trial. It is a 100% virtual, open-label, randomized controlled trial. It included 2,704 participants, aged 21 years or older, with anxiety, sleep disorders or chronic pain. Fourteen groups were formed: 13 groups of 208 individuals each received one of the 13 oral CBD extracts available for sale and the 14th group was a control group (n=296).

The primary endpoint in the study was “a distinct and palpable improvement in quality of life.”

The Study Results Are Promising

The secondary endpoints were:

an improvement in sleep assessed from the Promis Sleep Short Form,
a decrease in anxiety as assessed by the Promise Anxiety Scale and the General Anxiety Disorder-7 (GAD-7).

Intermediate study results were encouraging:

consumers reported an average 71% improvement in well-being,
63% reported a decrease in anxiety,
61% had an improvement in sleep.
Regarding pain, less than half of the participants experienced an improvement related to CBD use (47%).

Does CBD Have a Placebo Effect?

In a double-blind study, neither the patient nor the doctor knows which drug the patient has received. This allows for a maximum level of evidence. This is not the case here where the patients know the content of the treatment. Moreover, the craze for CBD is currently very important. It has an excellent reputation among consumers, which may distort people’s feelings. Nevertheless, in view of these data, this substance deserves to be tested in an additional study following the recommendations of good practice.

(Photo by Nik Shuliahin on Unsplash)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in futura-sciences, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Andrew Ross

Andrew Ross is a features writer whose stories are centered on emerging economies and fast-growing companies. His articles often look at trade policies and practices, geopolitics, mining and commodities, as well as the exciting world of technology. He also covers industries that have piqued the interest of the stock market, such as cryptocurrency and cannabis. He is a certified gadget enthusiast.